Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Alitretinoin is a synthetic retinoid with the molecular formula C23H28O4 and CAS Registry Number 59670-10-9. Structurally, it belongs to the class of third-generation retinoids and acts as a potent agonist for both retinoic acid receptor (RAR) and retinoid X receptor (RXR). This unique dual mechanism of action allows Alitretinoin to modulate cellular differentiation, proliferation, and apoptosis more effectively than earlier generations of retinoids. It is primarily synthesized through complex organic chemical processes involving the modification of vitamin A derivatives to enhance its stability and therapeutic index.
The most significant clinical application of Alitretinoin is the treatment of chronic hand eczema, specifically in cases that have proven resistant to potent topical corticosteroids. Approved by regulatory bodies such as the European Medicines Agency (EMA) and the US FDA under specific brand names like Panretin or Trexan, it serves as a systemic therapy for severe, disabling eczema affecting the hands. The drug works by reducing inflammation, normalizing keratinization, and restoring the skin barrier function, thereby alleviating symptoms like scaling, fissures, and intense itching. Unlike some other retinoids, Alitretinoin demonstrates high selectivity for the skin, minimizing systemic side effects when used topically or orally at prescribed doses.
Beyond dermatology, research has explored its potential in oncology due to its ability to induce tumor cell differentiation and inhibit angiogenesis. However, its primary commercial and medical utility remains firmly rooted in managing refractory inflammatory skin conditions. Patients taking Alitretinoin require careful monitoring for potential adverse effects, including dryness of the lips and mucous membranes, elevated lipid levels, and strict contraception requirements due to its known teratogenicity. The development of Alitretinoin marked a significant advancement in treating difficult-to-manage eczema, offering a non-steroidal alternative that improves quality of life for thousands of patients worldwide. Its precise molecular structure ensures targeted delivery to skin tissues, making it a cornerstone in modern dermatological pharmacotherapy for chronic inflammatory disorders.